ACADIA Pharmaceuticals Inc. (ACAD)
市前：
ACADIA Pharmaceuticals Inc.
12830 El Camino Real
Suite 400
San Diego, CA 92130
United States
858 558 2871
https://www.acadia.com
版塊: Healthcare
行業: Biotechnology
全職員工: 597
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Stephen R. Davis J.D. | President, CEO & Director | 1.77M | 927.35k | 1961 |
| Mr. Mark C. Schneyer | Executive VP & CFO | 821.81k | 無 | 1974 |
| Mr. Brendan P. Teehan | Executive VP, COO & Head of Commercial | 849.2k | 無 | 1969 |
| Mr. James K. Kihara | VP, Chief Accounting Officer & Corporate Controller | 無 | 無 | 1981 |
| Dr. Elizabeth H.Z. Thompson Ph.D. | Executive VP and Head of Research & Development | 無 | 無 | 1976 |
| Mr. Benir Ruano | Senior Vice President of Technical Development & Operations | 無 | 無 | 無 |
| Mr. Albert S. Kildani | Senior Vice President of Investor Relations & Corporate Communications | 無 | 無 | 無 |
| Ms. Jennifer J. Rhodes J.D. | Executive VP, Chief Legal Officer & Secretary | 無 | 無 | 1970 |
| Ms. Julie Fisher | Senior Vice President of Marketing & Commercial Strategy | 無 | 無 | 無 |
| Ms. Holly Valdiviez | Senior VP & Head of Sales | 無 | 無 | 無 |
描述
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
公司管治
截至 2024年5月1日 止，ACADIA Pharmaceuticals Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：8；董事會：4；股東權利：8；現金賠償：10。
